 |
Toll-Free: 1 800 518 4879
|
 |
Frost&Sullivan on HPLF
(HTML or PDF 43kb)
Corp. Headquarters
60 State Street, Suite 700
Boston, MA 02109
Toll-Free: 1-800-518-4879
investors@hepalife.com
Filings, news, quotes:
HPLF.OB
Investor |
|
Press Releases HepaLife is Recognized by Frost and Sullivan for Making Flu Vaccines Faster and Cheaper (HTML or PDF 43kb) Fiscal YearQuarterly Cycle: Corporate Headquarters 60 State St. Suite 700 USDA Research Laboratories:Growth Biology Biotechnology and Germplasm |
Board of DirectorsMr. Harmel S. Rayat, Scientific CollaboratorsDr. Neil C. Talbot Scientific Advisory BoardDr. Paul Coussens
Investor RelationsLaura Rivers-Bowerman |
HepaLife Technologies, Inc. (OTCBB: HPLF) is a development stage biotechnology company focused on the identification, development and eventual commercialization of cell-based technologies and products.
Current cell-based technologies under development by HepaLife include:
- The first-of- its-kind artificial liver device,
- Proprietary in-vitro toxicology and pre-clinical drug testing platforms, and
- Cell-culture based vaccines to protect against the spread of influenza viruses among humans, including potentially the high pathogenicity H5N1 virus.
Links:
Press Releases
Discover our history in the Press Release archive.
Medical Technologies
Our current and upcoming projects.
Scientific Collaborators
An introduction to our research and development team.
Scientific Advisory Board
Our team of scientific advisors.
Investor Relations
Our board of directors, corporate information and administrative team.
 | ©2006 HepaLife Technologies Inc. (disclaimer) Toll-Free: 1 800 518 4879 |  |
